Fundraising Fox
OS Therapies
NYSE: OSTXGrasonville, US · Founded 2018 · Delaware corporation · 2 known investors
Find your way into OS Therapies
1,447 people in our graph share verified history with the OS Therapies team — schools, employers, funds. One of them is your warm intro.
Beth Seidenbergunlockedknows Paul Romness · together at Amgen (overlapped)
×2knows the team · via Amgen
×8knows the team · via Johnson & Johnson
knows the team · via Orionis Biosciences
OS Therapies (OST) is a clinical-stage cancer immunotherapy company developing treatments that activate the immune system to target HER2-expressing cancers, initially focusing on osteosarcoma in children and adults. It plans to expand its lead candidate into breast, colorectal, esophageal, lung, ovarian, and pancreatic cancers and other solid tumors.
Founders & leadership
OS Therapies was founded in 2018 by Paul A. Romness.
PA
Paul A. RomnessFounder · CEOFounder and CEO of OS Therapies, a clinical-stage cancer immunotherapy company. Romness has held senior roles in biopharmaceutical companies spanning corporate strategy, business development, sales and marketing, product development, and government affairs.
CP
Christopher P. AcevedoChief Financial OfficerChristopher P. Acevedo is CFO of OS Therapies, a clinical-stage cancer immunotherapy company. He previously worked in public accounting at a major U.S. firm focusing on real estate audits, later transitioned to tax work managing portfolios and advising closely held businesses, and has experience executing acquisitions and taking companies public.
RG
Robert G. PetitChief Medical Officer and Chief Scientific OfficerRobert G. Petit is Chief Medical Officer and Chief Scientific Officer at OS Therapies, a clinical-stage cancer immunotherapy company. He has held executive and scientific roles in immunology and oncology drug development at both major pharmaceutical companies and biotechs, including leading the US medical team for Yervoy through regulatory approval and commercial launch, discovering the mechanism of action for Saforis and advancing it through Phase 3 clinical trials at Aesgen Inc., and contributing to the invention of multiple cancer immunotherapy candidates.
GC
Gerald CommissiongChief Business OfficerGerald Commissiong served as CEO of Todos Medical, an in-vitro diagnostics company developing blood tests for early cancer and neurodegenerative disease detection, and as president and executive chairman of Amarantus Bioscience Holdings, a biopharmaceutical company developing therapies and diagnostics across multiple disease areas. He is currently a managing partner at Fortitude Advisors, providing executive and financial advisory services to biotechnology companies.
PR
Paul RomnessCEOPaul Romness is founder and CEO of OS Therapies, a clinical-stage cancer immunotherapy company developing HER2-targeted treatments. He has held senior executive roles in biopharmaceutical companies focused on strategy, business development, and commercial operations.
Board
JC
John CiccioBoard director
TF
Theodore F. SearchBoard director
OR
AM
Avril McKean DieserBoard director
CE
Craig EagleBoard director
Investors · 2
JefferiesreportedNew York
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$31.3M disclosed across 11 of 13 rounds · 1900–2026
▶$5MraisedAug 2026 · 10 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2026 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Christopher P. AcevedoExecutive Officer
- John CiccioDirector
- Avril McKean DieserDirector
- Craig EagleDirector
- Olivier JarryDirector
- Theodore F. SearchDirector
- Offering amount
- $10M
- Amount sold
- $5M
- Sales commissions
- $500K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedJul 2026 · 1 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJul 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Christopher P. AcevedoExecutive Officer
- John CiccioDirector
- Avril McKean DieserDirector
- Craig EagleDirector
- Olivier JarryDirector
- Theodore F. SearchDirector
- Offering amount
- $9.3M
- Amount sold
- $1.6M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedMar 2026 · 9 investors · BiotechnologyRule 506(b)
▶$2MraisedMar 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Theodore F. SearchDirector
- Paul A. RomnessExecutive Officer, Director
- Karim GalzahrDirector
- Olivier JarryDirector
- Christopher P. AcevedoExecutive Officer
- John CiccioDirector
- Avril McKean DieserDirector
- Robert G. PetitExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $140K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.5MraisedJan 2026 · 9 investors · BiotechnologyRule 506(b)
▶$3.5MraisedJan 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John CiccioDirector
- Avril McKean DieserDirector
- Olivier JarryDirector
- Christopher P. AcevedoExecutive Officer
- Theodore F. SearchDirector
- Robert G. PetitExecutive Officer
- Karim GalzahrDirector
- Paul A. RomnessExecutive Officer, Director
- Offering amount
- $7.5M
- Amount sold
- $3.5M
- Sales commissions
- $627.5K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedSep 2025 · 10 investors · BiotechnologyRule 506(b)
▶$3.8MraisedSep 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Avril McKean DieserDirector
- Christopher P. AcevedoExecutive Officer
- Karim GalzahrDirector
- Robert G. PetitExecutive Officer
- John CiccioDirector
- Theodore F. SearchDirector
- Olivier JarryDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- Sales commissions
- $56.7K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedJul 2025 · 27 investors · BiotechnologyRule 506(b)
▶$4.2MraisedJul 2025 · 27 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John CiccioDirector
- Olivier JarryDirector
- Karim GalzahrDirector
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Christopher P. AcevedoExecutive Officer
- Theodore F. SearchDirector
- Avril McKean DieserDirector
- Offering amount
- $4.2M
- Amount sold
- $4.2M
- Sales commissions
- $210.8K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.1MraisedJan 2025 · 34 investors · PharmaceuticalsRule 506(b)
▶$7.1MraisedJan 2025 · 34 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Avril McKean DieserDirector
- John CiccioDirector
- Christopher P. AcevedoExecutive Officer
- Theodore F. SearchDirector
- Paul A. RomnessExecutive Officer, Director
- Robert G. PetitExecutive Officer
- Gerald CommissiongExecutive Officer
- Olivier R. JarryDirector
- Offering amount
- $10M
- Amount sold
- $7.1M
- Minimum investment
- $10K
- Sales commissions
- $240K
- Placement agents
- Arcadia Securities, LLC, Ceros Financial Services, Inc.
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$700KraisedDec 2023 · 3 investors · BiotechnologyRule 506(b)
▶$700KraisedDec 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul A. RomnessExecutive Officer, Director
- Colin GoddardDirector
- Theodore F. SearchDirector
- Joacim BorgDirector
- Christopher P. AcevedoExecutive Officer
- Robert G. PetitExecutive Officer
- John CiccioDirector
- Offering amount
- $2M
- Amount sold
- $700K
- Minimum investment
- $50K
- Sales commissions
- $70K
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$73.8Mvaluation at IPOAug 2024 · $4.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlap
Robinhood20 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits17 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Artios Pharma16 shared keywordsArtios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.
Seeking Alpha15 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with OS Therapies for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does OS Therapies do?
- OS Therapies (OST) is a clinical-stage cancer immunotherapy company developing treatments that activate the immune system to target HER2-expressing cancers, initially focusing on osteosarcoma in children and adults. It plans to expand its lead candidate into breast, colorectal, esophageal, lung, ovarian, and pancreatic cancers and other solid tumors.
- Who founded OS Therapies?
- OS Therapies was founded by Paul A. Romness in 2018.
- Who are OS Therapies's investors?
- OS Therapies's investors include K20 Fund, Jefferies.
- How much funding has OS Therapies raised?
- OS Therapies has disclosed $31.3M raised across 11 of its 13 known rounds.
- Where is OS Therapies headquartered?
- OS Therapies is headquartered in Grasonville, US.